Phaseline

Targets › HAVCR2

HAVCR2 (Hepatitis A virus cellular receptor 2): drug programs, companies and trials

9 programs from 9 companies in 16 trials: 10 Phase 1, 6 Phase 2; Oncology; next expected readout Dec 2026.

Cell surface receptor implicated in modulating innate and adaptive immune responses. Generally accepted to have an inhibiting function. (UniProt, Q8TDQ0)

Open in Phaseline: the race on HAVCR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKCobolimab
Hepatitis A virus cellular receptor 2 inhibitor
HAVCR2Phase 2Lung Cancer, Non-Small Cell; Melanoma; Neoplasms; Cervical Cancer …Dec 2026
University of WashingtonVerzistobart
TIM-3 inhibitor monoclonal antibody
HAVCR2Phase 2Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8Jan 2027
NovartisSabatolimab (MBG453)
Hepatitis A virus cellular receptor 2 inhibitor
HAVCR2Phase 2Myelodysplastic SyndromesFeb 2028
L & L Bio Co., Ltd., Ningbo, ChinaLB1410
anti-PD-1 and anti-TIM-3 bispecific antibody
PDCD1, HAVCR2Phase 1Solid TumorDec 2026
Xuzhou Medical Universityanti Tim-3/CD123 CAR-T cell therapy
Dual-targeted CAR-T cell therapy targeting Tim-3 and CD123
HAVCR2, CD123Phase 1Acute Myeloid Leukemia RefractoryJan 2027
TesaroCobolimab (TSR-022)
Hepatitis A virus cellular receptor 2 inhibitor
HAVCR2Phase 1NeoplasmsMar 2027
Servier Bio-InnovationS095018
Anti-TIM3 antibody
HAVCR2Phase 1Non-small Cell Lung Cancer (NSCLC)Apr 2027
AstraZenecaAZD7789 (sabestomig)
anti-PD-1 and anti-TIM-3 bispecific antibody
PDCD1, HAVCR2Phase 1Carcinoma, Non-Small-Cell Lung; Advanced or Metastatic NSCLCMay 2027
Merck & Co. (MSD)Boserolimab
TIM-3 inhibitor
HAVCR2Phase 1Carcinoma, Non-Small-Cell LungFeb 2032

Conditions

Solid Tumor (2) Neoplasms (2) Carcinoma, Non-Small-Cell Lung (2) Myelodysplastic Syndromes (1) Lung Cancer, Non-Small Cell (1) Melanoma (1) Cervical Cancer (1) Adult Primary Liver Cancer (1) Melanoma Stage III (1) Non-small Cell Lung Cancer (NSCLC) (1) Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 (1) Acute Myeloid Leukemia Refractory (1)

Modalities

mixed (5), antibody (2), small molecule (1), other (1)

Companies

L & L Bio Co., Ltd., Ningbo, China (1) Novartis (1) GSK (1) Merck & Co. (MSD) (1) Servier Bio-Innovation (1) University of Washington (1) Xuzhou Medical University (1) AstraZeneca (1) Tesaro (1)

Related targets

PDCD1 (2) CD123 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.